title: Three-dimensional MR imaging of pulmonary vessels and parenchyma with NC100150 injection (Clariscan).
abstract: The influence of increasing doses of NC100150 Injection (Clariscantrade mark) and echo times on visualization of pulmonary vessels and parenchyma was evaluated. The effects of 0.5, 1, 2, 4, and 8 mg Fe/kg NC100150 Injection and echo times (TE) of 1.1, 1.8, 2. 2, and 4.3 msec were determined in six dogs using breath-hold three-dimensional (3D) spoiled gradient-echo magnetic resonance (MR) sequence. At 2 mg Fe/kg and TE of 1.1 msec, the signal-to-noise ratio of the central pulmonary arteries and parenchyma was significantly increased (5.3 +/- 2.2 to 50.3 +/- 2.4) and (2.2 +/- 0. 9 to 6.4 +/- 1.1), respectively. Using the TE of 1.1 msec, signal intensity in the main arteries continued to increase with increasing dose. Moreover, the enhancement of pulmonary parenchyma and microvasculature had a positive dose response. 3D MR imaging with ultrashort echo time and 2 mg Fe/kg NC100150 Injection produces angiograms with strong vascular contrast and allows qualitative assessment of pulmonary parenchyma and microvasculature.
authors.affiliation: Department of Radiology, University of California San Francisco, San Francisco, California 94143-0628, USA.
authors.forename: J
authors.initials: J
authors.lastname: Bremerich
authors.forename: T P
authors.initials: TP
authors.lastname: Roberts
authors.forename: M F
authors.initials: MF
authors.lastname: Wendland
authors.forename: R
authors.initials: R
authors.lastname: Wyttenbach
authors.forename: H
authors.initials: H
authors.lastname: Arheden
authors.forename: G P
authors.initials: GP
authors.lastname: Reddy
authors.forename: N
authors.initials: N
authors.lastname: Shafaghi
authors.forename: C B
authors.initials: CB
authors.lastname: Higgins
authors.forename: M
authors.initials: M
authors.lastname: Saeed
mesh_terms: D000818:Animals; D003287:Contrast Media / Q000008:administration & dosage*; D003911:Dextrans; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D052203:Ferrosoferric Oxide; D007089:Image Enhancement / Q000379:methods*; D007501:Iron; D008168:Lung / Q000473:pathology*; D008171:Lung Diseases / Q000175:diagnosis; D018810:Magnetic Resonance Angiography / Q000379:methods*; D058185:Magnetite Nanoparticles; D008297:Male; D010087:Oxides; D011336:Probability; D011651:Pulmonary Artery / Q000473:pathology*; D011652:Pulmonary Circulation; D012680:Sensitivity and Specificity
chemical_list: D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D010087:Oxides; C097921:ferumoxtran-10; D007501:Iron; D052203:Ferrosoferric Oxide